Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

Regulatory

December 30, 2024

Change in the number of shares and votes in Egetis Therapeutics

Read more

December 18, 2024

Egetis highlights the positive CHMP opinion for Emcitate®, recent major milestones, and gives a corporate update at Investor Day in Stockholm today

Read more

Regulatory

December 16, 2024

Issuance and repurchase of class C shares for incentive programs

Read more

Upcoming event

January 13-14, 2025

JP Morgan week, San Francisco

Latest presentation

December 18, 2024

Egetis Investor Day

Latest Report

November 8, 2024

Interim report Q3 2024

Calendar and upcoming reports

January 13-14, 2025

JP Morgan week, San Francisco

February 26, 2025

Year-end Report Q4 2024 (7:00am CET)

April 30, 2025

Interim Report Q1 2025 (7:00am CEST)

May 6, 2025

Annual General Meeting

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]